Management of Ovarian Cancer in Patients Older Than 80 Years of Age

• Published in: Gynecologic oncology Vol. 73; no. 1; pp. 137 - 139
• Main Authors: Cloven, Noelle Gillette, Manetta, Alberto, Berman, Michael L., Kohler, Matthew F., DiSaia, Phillip J.
• Format: Journal Article
• Language: English
• Published: San Diego, CA Elsevier Inc 01.04.1999; Elsevier
• Subjects: Age Factors; Aged; Aged, 80 and over; Biological and medical sciences; Carcinoma - therapy; Female; Female genital diseases; Gynecology. Andrology. Obstetrics; Humans; Medical sciences; Ovarian Neoplasms - therapy; Retrospective Studies; Treatment Outcome; Tumors; Age 80-89; Human; Prognosis; Indication; Malignant tumor; Survival; Morbidity; Female genital diseases; Ovarian diseases; Ovary; Treatment; Age of onset; Age 90-99; Female
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1006/gyno.1998.5337

Objective.The objective of this study was to examine the treatment, associated morbidity, and survival in very elderly patients with epithelial ovarian cancer. Methods.A retrospective analysis of patients 80 years of age and older treated for epithelial ovarian cancer by the Gynecologic Oncology faculty at the University of California Irvine was performed. Results.Eighteen patients were older than 80 years of age at the time of diagnosis of ovarian cancer. Median age was 83 years (range 80–86 years). There were 2 stage I, 10 stage IIIC, 4 stage VI, and 2 unstaged patients. One patient had a tumor of low malignant potential, 4 patients had grade II tumors, and 10 patients had tumors that were grade III. Eighty-three percent of patients had one or more preexisting medical illnesses. Cardiac disease, stroke, and hypertension were most common. Sixteen of 18 patients (88%) underwent primary debulking surgery. American Society of Anesthesiologists physical status classification was as follows: 7/16 (44%) class II, 6/16 (38%) class III, and 2/16 (13%) class IV. The procedures performed included 16 bilateral salpingo-oophorectomies, 11 total abdominal hysterectomies, 16 omentectomies, 3 lymph node dissections, and 7 bowel resections. Four (25%) patients were optimally cytoreduced to <1 cm of residual disease. Seventy-five percent of surgical patients received blood transfusions of 2 or more units PRBC. Mean EBL was 600 cc (range 200–4200 cc). Thirty-eight percent of patients experienced major postoperative morbidity. There were 7 patients with postoperative congestive heart failure, 3 with sepsis, 1 with aspiration pneumonia, and 2 postoperative deaths. Seventy-five percent of patients spent time in the intensive care unit. Median number of days was 3 (range 1–22 days). Mean postoperative stay was 8 days (range 6–57 days). Sixty-five percent of patients were discharged to home. The other patients were discharged to intermediate care facilities or nursing homes. Eighty-three percent of patients received chemotherapy. Of the 10 patients (63%) receiving adjuvant chemotherapy, the mean interval from surgery to initiation of therapy was 3 weeks (range 1–4 weeks). Overall median survival was 6 months (range 1–45 months). Median survival in patients with optimal debulking was 32.5 months (range 7–45 months) compared to 3.5 months (range 1–41 months) in patients suboptimally debulked. Conclusions.In patients older than 80 years of age who undergo debulking surgery for ovarian cancer, serious medical comorbidity and advanced ASA status are common. Despite aggressive surgical effort and frequent blood transfusions, optimal debulking to less than 1 cm is achieved in only 25% of patients. Impressive morbidity and mortality occurs in this group of patients, but most patients are discharged to home and are able to receive postoperative chemotherapy.